Announcements Trials
Browse Landscape

Phase

Phase 2 45Phase 1 21Phase 1/2 18Phase 3 5Phase NA 4Phase 4 3Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Warts 1Neutropenia 1Infections 1Immunologic Deficiency Syndromes 1Agammaglobulinemia 1

Interventions

Cisplatin 98Gemcitabine 66Paclitaxel 62Carboplatin 60Fluorouracil 59Docetaxel 59Capecitabine 59Oxaliplatin 56Cyclophosphamide 54Radiotherapy 50Drug Therapy 46Bevacizumab 38pembrolizumab 35Dexamethasone 33Magnetic Resonance Spectroscopy 32Leucovorin 32Doxorubicin 31Cytarabine 27Etoposide 26Pemetrexed 25Nivolumab 24Methotrexate 24Radiation 20Vincristine 18venetoclax 17apatinib 17Rituximab 17Prednisone 17Letrozole 17Irinotecan 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Interventional × plerixafor × Clear all
NCT02231879 2023-04-07

Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2/3 Completed
20 enrolled 10 charts

Agammaglobulinemia, Immunologic Deficiency Syndromes, Infections, Neutropenia, Warts

Data powered by HemOnc (CC BY 4.0) Colophon âš¡